Seattle Genetics' lymphoma data are promising

Fuller clinical-trial results will be released in June By JOSEPH TARTAKOFF P-I REPORTER Seattle Genetics released data late Thursday indicating that the majority of lymphoma patients who had taken the company's SGN-35 treatment at higher doses saw their tumors shrink. The trial is ongoing, but... [read full story]